WO2002036162A3 - Compositions for treatment of ocular neovascularization and neural injury - Google Patents

Compositions for treatment of ocular neovascularization and neural injury Download PDF

Info

Publication number
WO2002036162A3
WO2002036162A3 PCT/US2001/046014 US0146014W WO0236162A3 WO 2002036162 A3 WO2002036162 A3 WO 2002036162A3 US 0146014 W US0146014 W US 0146014W WO 0236162 A3 WO0236162 A3 WO 0236162A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
ocular neovascularization
neural injury
neural
Prior art date
Application number
PCT/US2001/046014
Other languages
French (fr)
Other versions
WO2002036162A2 (en
Inventor
James A Burke
Ton Lin
Larry A Wheeler
Vries Gerald W De
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to JP2002538971A priority Critical patent/JP4198988B2/en
Priority to DE60138137T priority patent/DE60138137D1/en
Priority to AU3056702A priority patent/AU3056702A/en
Priority to EP01990804A priority patent/EP1353692B1/en
Priority to AU2002230567A priority patent/AU2002230567B2/en
Priority to CA2427655A priority patent/CA2427655C/en
Publication of WO2002036162A2 publication Critical patent/WO2002036162A2/en
Publication of WO2002036162A3 publication Critical patent/WO2002036162A3/en
Priority to HK04101890.5A priority patent/HK1059037A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Methods and compositions for the treatment of ocular neovascularization (CNV) and macular degeneration. The invention includes combining laser treatment with administration of a neuroprotectant.
PCT/US2001/046014 2000-11-01 2001-11-01 Compositions for treatment of ocular neovascularization and neural injury WO2002036162A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2002538971A JP4198988B2 (en) 2000-11-01 2001-11-01 Methods and compositions for treating ocular neovascularization and nerve injury
DE60138137T DE60138137D1 (en) 2000-11-01 2001-11-01 METHOD AND COMPOSITIONS FOR TREATING OCCULAR NEOVASCULARIZATION AND NERVE INJURY
AU3056702A AU3056702A (en) 2000-11-01 2001-11-01 Methods and compositions for treatment of ocular neovascularization and neural injury
EP01990804A EP1353692B1 (en) 2000-11-01 2001-11-01 Methods and compositions for treatment of ocular neovascularization and neural injury
AU2002230567A AU2002230567B2 (en) 2000-11-01 2001-11-01 Compositions for treatment of ocular neovascularization and neural injury
CA2427655A CA2427655C (en) 2000-11-01 2001-11-01 Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization
HK04101890.5A HK1059037A1 (en) 2000-11-01 2004-03-15 Methods and compositions for treatment of ocular neovascularization and neural injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24485000P 2000-11-01 2000-11-01
US60/244,850 2000-11-01

Publications (2)

Publication Number Publication Date
WO2002036162A2 WO2002036162A2 (en) 2002-05-10
WO2002036162A3 true WO2002036162A3 (en) 2003-08-21

Family

ID=22924381

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/051062 WO2002058730A2 (en) 2000-11-01 2001-10-26 Compositions for treatment of ocular neovascularization
PCT/US2001/046014 WO2002036162A2 (en) 2000-11-01 2001-11-01 Compositions for treatment of ocular neovascularization and neural injury

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051062 WO2002058730A2 (en) 2000-11-01 2001-10-26 Compositions for treatment of ocular neovascularization

Country Status (10)

Country Link
US (1) US20020094998A1 (en)
EP (1) EP1353692B1 (en)
JP (1) JP4198988B2 (en)
AT (1) ATE426413T1 (en)
AU (3) AU2002248284A1 (en)
CA (1) CA2427655C (en)
DE (1) DE60138137D1 (en)
ES (1) ES2322030T3 (en)
HK (1) HK1059037A1 (en)
WO (2) WO2002058730A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138480B2 (en) 2009-11-09 2015-09-22 Allergan, Inc. Compositions and methods for stimulating hair growth
US9144543B2 (en) 2004-04-30 2015-09-29 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US9161938B2 (en) 2004-04-30 2015-10-20 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8256433B2 (en) * 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US20080138398A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US20080138294A1 (en) * 1999-07-16 2008-06-12 Igor Gonda Systems and methods for effecting cessation of tobacco use
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
EP1549305B1 (en) * 2002-10-08 2009-04-22 Allergan, Inc. Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of morbus alzheimer and morbus parkinson
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
BR0315931A (en) * 2002-10-31 2005-09-13 Celgene Corp Method of treating, preventing or controlling macular degeneration and pharmaceutical composition
CA2530166A1 (en) * 2003-03-07 2004-09-23 Randolph D. Glickman Antibody-targeted photodynamic therapy
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7992570B2 (en) * 2004-04-22 2011-08-09 Light Sciences Oncology, Inc. Fractionated light PDT therapy for posterior eye disease
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
BRPI0510485A (en) 2004-04-30 2007-11-13 Allergan Inc biodegradable intravitreal tyrosine kinase inhibitor implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2006012521A2 (en) * 2004-07-22 2006-02-02 Vanda Pharmaceuticals, Inc. Treatment for ocular disease
KR20070054213A (en) 2004-09-24 2007-05-28 알러간, 인코포레이티드 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
BRPI0516950A (en) 2004-09-24 2008-09-30 Allergan Inc 4- (cyclically condensed methyl) -imidazol-2-thionas acting as alpha2 adrenergic agonists
JP2008514603A (en) 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド 4- (Heteroaryl-methyl and substituted heteroaryl-methyl) -imidazol-2-thiones as α2 adrenergic agonists
NZ553566A (en) 2004-09-28 2010-11-26 Allergan Inc Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
WO2006057859A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
EP2119439A3 (en) * 2005-05-17 2010-01-27 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor for treating macular degeneration
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
ES2329636B2 (en) 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) USE OF PEDF FACTOR TO INDUCE MOTHER CELLS SELF-RENEWAL
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US9132119B2 (en) * 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8629172B2 (en) * 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8883768B2 (en) 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
CA2776748A1 (en) * 2009-10-08 2011-04-14 Neurotech Usa, Inc. Use of pedf in an encapsulated cell-based delivery system
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
KR102126007B1 (en) 2010-01-22 2020-06-24 알러간, 인코포레이티드 Intracameral sustained release therapeutic agent implants
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
PL2605771T3 (en) * 2010-08-16 2018-10-31 Allergan, Inc. Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
CN109602691A (en) 2013-02-15 2019-04-12 阿勒根公司 Sustained drug delivery implantation material

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040245A1 (en) * 1999-01-04 2000-07-13 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury
WO2002064163A2 (en) * 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
ATE406914T1 (en) * 2000-02-10 2008-09-15 Massachusetts Eye & Ear Infirm PHOTODYNAMIC THERAPY FOR THE TREATMENT OF EYE DISEASES
CA2403612A1 (en) * 2000-03-24 2001-10-11 Romulus Kimbro Brazzell Improved treatment of neovascularization

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040245A1 (en) * 1999-01-04 2000-07-13 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury
WO2002064163A2 (en) * 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9144543B2 (en) 2004-04-30 2015-09-29 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US9161938B2 (en) 2004-04-30 2015-10-20 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US9138480B2 (en) 2009-11-09 2015-09-22 Allergan, Inc. Compositions and methods for stimulating hair growth

Also Published As

Publication number Publication date
ES2322030T3 (en) 2009-06-16
US20020094998A1 (en) 2002-07-18
DE60138137D1 (en) 2009-05-07
EP1353692B1 (en) 2009-03-25
ATE426413T1 (en) 2009-04-15
EP1353692A2 (en) 2003-10-22
WO2002058730A3 (en) 2003-05-15
AU3056702A (en) 2002-05-15
CA2427655A1 (en) 2002-05-10
AU2002230567B2 (en) 2007-01-18
JP2004512378A (en) 2004-04-22
HK1059037A1 (en) 2004-06-18
AU2002248284A1 (en) 2002-08-06
JP4198988B2 (en) 2008-12-17
WO2002036162A2 (en) 2002-05-10
WO2002058730A2 (en) 2002-08-01
CA2427655C (en) 2011-07-26

Similar Documents

Publication Publication Date Title
WO2002036162A3 (en) Compositions for treatment of ocular neovascularization and neural injury
AU2003301961A1 (en) Intraocular administration of cyclosporin a for the treatment of macular degeneration, retinopathy or retinitis pigmentosa
WO2007044668A3 (en) Compstatin and analogs thereof for eye disorders
WO2006042329A8 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
EP0998925A4 (en) Medicinal compositions for topical administration containing vitamin d and vitamin k
WO2005014046A3 (en) Compositions for delivery of therapeutics into the eyes and methods for making and using the same
BR9307077A (en) Process for adjusting the corneal shape of an eye and intrastromal corneal ring
MXPA03008401A (en) Combination of brimonidine and timolol for topical ophthalmic use.
WO2006019893A3 (en) Intrastromal devices and method for improving vision
WO2002085248A3 (en) Prostanoids augment ocular drug penetration
GB9923076D0 (en) Sapogenin derivatives and their use
WO2003022174A3 (en) Intraocular lens extracting device
WO2003006893A3 (en) Methods of inhibiting amyloid toxicity
WO2003005941A3 (en) Insert for the treatment of dry eye
EP1050308A4 (en) Preventives or remedies for vision disorders
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
WO2001074389A3 (en) Improved treatment of neovascularization
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
BR0017163A (en) 5-Hydroxyindazole Derivatives for Glaucoma Treatment
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
BR0314419A (en) Substituted 5-chroman-5-yl-ethylamine compounds, their use and pharmaceutical composition including
MXPA03007500A (en) Refractive anterior chamber intraocular implant.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001990804

Country of ref document: EP

Ref document number: 2427655

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002538971

Country of ref document: JP

Ref document number: 2002230567

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001990804

Country of ref document: EP